Skip to main content

Advertisement

SpringerLink
Log in

Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature

  • Gynecologic Cancers (NS Reed, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

For many years hormonal treatment has played a role in the treatment of a selected group of patients with a variety of recurrent or metastatic gynaecological cancers, including ovarian and endometrial carcinomas, endometrial stromal sarcomas and granulosa cell tumours. Hormonal agents that are typically used include luteinizing-hormone-releasing hormone analogues, progestogens, selective oestrogen-receptor-modulating drugs such as tamoxifen, and more recently aromatase inhibitors. The rates of response to these drugs differ considerably depending on the tumour type, disease grade and stage as well as the type of drug used. Patients with granulosa cell tumours and endometrial stromal sarcomas have the highest response rates; owing to the rarity of these tumour types, the documented response rates are based on case reports and small series. Response rates in patients with recurrent and metastatic endometrial and ovarian carcinoma have been lower. It has been suggested that patients with well-differentiated and hormone-receptor-positive carcinomas are more likely to benefit from hormonal treatment. However, the data to support this are limited, and at times conflicting, with very few prospective studies to date. This review updates the evidence for the use of hormonal treatment in patients with potentially hormone responsive recurrent and metastatic gynaecological cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–78.

    Article  PubMed  CAS  Google Scholar 

  2. • Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer. 2012;19(6):R255–79. This article gives a comprehensive overview of the role of hormones in the pathogenesis and treatment of ovarian cancer.

    Article  PubMed  CAS  Google Scholar 

  3. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466–71.

    Article  PubMed  CAS  Google Scholar 

  4. AlHilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012;38(1):340–4.

    Article  PubMed  CAS  Google Scholar 

  5. Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005;96(3):865–9.

    Article  PubMed  Google Scholar 

  6. • Altman AD, Nelson GS, Chu P, Nation J, Ghatage P. Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer. 2012;22(6):1006–12. This article gives an overview of experience with aromatase inhibitors and the rationale to use these drugs in patients with uterine sarcoma.

    Article  PubMed  Google Scholar 

  7. • Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188–98. This article gives an overview of tumour biology of various types of uterine sarcomas and their recommended clinical management.

  8. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010;17(3), CD001034.

    Google Scholar 

  9. Du Bois A, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol. 2002;13(2):251–7.

    Article  Google Scholar 

  10. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol. 2010;119(3):444–50.

    Article  PubMed  CAS  Google Scholar 

  11. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol. 1993;11(10):1957–68.

    PubMed  CAS  Google Scholar 

  12. Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer. 1994;30A(5):697–8.

    Article  PubMed  CAS  Google Scholar 

  13. Wiernik PH, Greenwald ES, Ball H, Young JA, Vogl S. High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group study PD884. Am J Clin Oncol. 1998;21(6):565–7.

    Article  PubMed  CAS  Google Scholar 

  14. Balbi G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer. 2004;14(5):799–803.

    Article  PubMed  CAS  Google Scholar 

  15. Duffaud. D-TRP-6-LHRH (triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group study. Anticancer Drugs. 2001;12(2):159-62.

  16. Marinaccio M, D'Addario V, Serrati A, Pinto V, Cagnazzo G. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol. 1996;17(4):286–8.

    PubMed  CAS  Google Scholar 

  17. Zidan J, Zohar S, Mijiritzky I, Kral S, Bilenca B. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Isr Med Assoc J. 2002;4(8):597–9.

    PubMed  CAS  Google Scholar 

  18. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer. 2005;93(6):647–51.

    Article  PubMed  CAS  Google Scholar 

  19. Markman M. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol. 1996;62(1):4–6.

    Article  PubMed  CAS  Google Scholar 

  20. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991;68(2):269–71.

    Article  PubMed  CAS  Google Scholar 

  21. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008;19(1):16–27.

    Article  PubMed  CAS  Google Scholar 

  22. Aydiner A, Tas F. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. Trials. 2008;9:47.

    Article  PubMed  Google Scholar 

  23. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8(7):2233–9.

    PubMed  CAS  Google Scholar 

  24. del Carmen MG. Phase II trial of anastrozole in women with asymptomatic Müllerian cancer. Gynecol Oncol. 2003;91(3):596–602.

    Article  PubMed  Google Scholar 

  25. Papadimitriou CA. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004;66(2):112–7.

    Article  PubMed  CAS  Google Scholar 

  26. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams ARW, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor–positive patients. Clin Cancer Res. 2007;13(12):3617–22.

    Article  PubMed  CAS  Google Scholar 

  27. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110(1):56–9.

    Article  PubMed  CAS  Google Scholar 

  28. Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol. 1982;59(5):583–8.

    PubMed  CAS  Google Scholar 

  29. Weiner SA, Alberts DS, Surwit EA, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987;27(2):208–13.

    Article  PubMed  CAS  Google Scholar 

  30. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol. 2001;25(5):667–72.

    Article  PubMed  CAS  Google Scholar 

  31. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007;18(5):1051–9.

    PubMed  Google Scholar 

  32. Karaferic A, Jovanovic D, Jelic S. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. J BUON. 2009;14(4):635–9.

    PubMed  CAS  Google Scholar 

  33. Shafiee MN, Shan LP, Ahmad S, Idris N, Omar MH. The use of gonadotrophin-releasing hormone (GnRH) analogue in endometroid adenocarcinoma of the ovary: a case report and discussion. Eur J Obstet Gynecol Reprod Biol. 2012;161(1):110–1.

    Article  PubMed  Google Scholar 

  34. Pan Y, Kao MS. Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review. Current Oncol. 2010 Nov;17(6):82–5.

  35. Sieh W, Kobel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis Consortium study. Lancet Oncol. 2013;14(9):853–62.

    Article  PubMed  CAS  Google Scholar 

  36. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335968.

  37. Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev. 2010;19(4):982–91.

    Article  PubMed  CAS  Google Scholar 

  38. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  39. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106(2):325–33.

    Article  PubMed  CAS  Google Scholar 

  40. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol. 1991;9(6):1071–88.

    PubMed  CAS  Google Scholar 

  41. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand. 1984;63(5):441–50.

    Article  PubMed  CAS  Google Scholar 

  42. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1996;14(2):357–61.

    PubMed  CAS  Google Scholar 

  43. Fiorica JV. Phase II, trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–4.

    Article  PubMed  CAS  Google Scholar 

  44. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):4–9.

    Article  PubMed  CAS  Google Scholar 

  45. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.

    PubMed  CAS  Google Scholar 

  46. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14(4):650–8.

    Article  PubMed  CAS  Google Scholar 

  47. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78(2):212–6.

    Article  PubMed  CAS  Google Scholar 

  48. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010;12, CD007926.

    PubMed  Google Scholar 

  49. Singh M, Darcy KM, Brady WE, Clubwala R, Weber Z, Rittenbach JV, et al. Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. Gynecol Oncol. 2011;123(2):320–8.

    Article  PubMed  CAS  Google Scholar 

  50. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736.

    PubMed  CAS  Google Scholar 

  51. Kamoi S, Ohaki Y, Mori O, Yamada T, Fukunaga M, Takeshita T. Determining best potential predictor during high-dose progestin therapy for early staged and well-differentiated endometrial adenocarcinoma using semiquantitative analysis based on image processing and immunohistochemistry. J Nippon Med Sch. 2011;78(2):84–95.

    Article  PubMed  CAS  Google Scholar 

  52. Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer. 1991;27(9):1095–9.

    Article  PubMed  CAS  Google Scholar 

  53. Trope CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51(6):694–705.

    Article  PubMed  Google Scholar 

  54. Hendrickson MR, Tavassoli F, Kempson R, et al. Mesenchymal tumors of the uterus and related lesions. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumors. Lyon: IRAC; 2003. p. 233–44.

    Google Scholar 

  55. Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. Expert Rev Anticancer Ther. 2012;12(7):885–94.

    Article  PubMed  CAS  Google Scholar 

  56. Dahhan T, Fons G, Buist MR, Ten Kate FJ, van der Velden J. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2009;144(1):80–4.

    Article  PubMed  CAS  Google Scholar 

  57. Sylvestre VT, Dunton CJ. Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. Horm Cancer. 2010;1(2):112–5.

    Article  PubMed  Google Scholar 

  58. Lim MC, Lee S, Seo SS. Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma. Onkologie. 2010;33(5):260–2.

    Article  PubMed  CAS  Google Scholar 

  59. Garavaglia E, Pella F, Montoli S, Voci C, Taccagni G, Mangili G. Treatment of recurrent or metastatic low-grade endometrial stromal sarcoma: three case reports. Int J Gynecol Cancer. 2010;20(7):1197–200.

    Article  PubMed  Google Scholar 

  60. Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K. Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol. 2010;15(2):179–83.

    Article  PubMed  CAS  Google Scholar 

  61. Mizuno M, Yatabe Y, Nawa A, Nakanishi T. Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma. Int J Clin Oncol. 2012;17(4):348–54.

    Article  PubMed  CAS  Google Scholar 

  62. Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007;97(9):1194–9.

    Article  PubMed  CAS  Google Scholar 

  63. http://www.eortc.be/protoc/details.asp?protocol=55112.

  64. Tzakas E, Liu S, Todd RW, Redman CW. Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS). J Obstet Gynaecol. 2009;29(8):778–9.

    Article  PubMed  CAS  Google Scholar 

  65. Alkasi O, Meinhold-Heerlein I, Zaki R, Fasching P, Maass N, Jonat W, et al. Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report. Arch Gynecol Obstet. 2009;279(1):57–60.

    Article  PubMed  Google Scholar 

  66. Pautier P, Gutierrez-Bonnaire M, Rey A, Sillet-Bach I, Chevreau C, Kerbrat P, et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2008;18(3):446–52.

    Article  PubMed  CAS  Google Scholar 

  67. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;72(2):131–7.

    Article  PubMed  CAS  Google Scholar 

  68. Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev. 2008;34(1):1–12.

    Article  PubMed  CAS  Google Scholar 

  69. Martikainen H, Penttinen J, Huhtaniemi I, Kauppila A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol. 1989;35(3):406–8.

    Article  PubMed  CAS  Google Scholar 

  70. Malik ST, Slevin ML. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary–a new therapeutic approach? Br J Cancer. 1991;63(3):410–1.

    Article  PubMed  CAS  Google Scholar 

  71. Kauppila A, Bangah M, Burger H, Martikainen H. GnRH agonist analog therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol. 1992;6(4):271–4.

    Article  PubMed  CAS  Google Scholar 

  72. Isaacs R, Forgeson G, Allan S. Progestagens for granulosa cell tumours of the ovary. Br J Cancer. 1992;65(1):140.

    Article  PubMed  CAS  Google Scholar 

  73. Fishman A, Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Kaplan AL, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med. 1996;41(6):393–6.

    PubMed  CAS  Google Scholar 

  74. Briasoulis E, Karavasilis V, Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann Oncol. 1997;8(8):811–2.

    Article  PubMed  CAS  Google Scholar 

  75. Kim HJ, Lee SC, Bae SB, Kwon KW, Kim CK, Lee NS, et al. GnRH agonist therapy in a patient with recurrent ovarian granulosa cell tumors. J Korean Med Sci. 2009;24(3):535–8.

    Article  PubMed  Google Scholar 

  76. Abdul Munem A, Al-Bahrani B, Mehdi I, Kamona A, Nadas AM. Aromatase inhibitors–a viable option for recurrent granulosa cell tumour of ovary: overview and case report. J Paki Med Assoc. 2012;62(5):505–7.

    Google Scholar 

  77. Keskin S, Bengisu E, Tuzlali S, Aydiner A. Complete response in a patient with granulosa cell tumor treated with a combination of leuprolide and tamoxifen. Onkologie. 2012;35(7–8):451–3.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dirkje W Sommeijer, Katrin Sjoquist and Michael Friedlander declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

    Dirkje W. Sommeijer, Katrin M. Sjoquist & Michael Friedlander

  2. Australia New Zealand Gynaecological Oncology Group, Medical Foundation Building, 92-94 Parramatta Road, Camperdown, NSW, 2050, Australia

    Dirkje W. Sommeijer, Katrin M. Sjoquist & Michael Friedlander

  3. Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia

    Katrin M. Sjoquist

  4. Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia

    Michael Friedlander

Authors
  1. Dirkje W. Sommeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katrin M. Sjoquist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Friedlander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirkje W. Sommeijer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sommeijer, D.W., Sjoquist, K.M. & Friedlander, M. Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature. Curr Oncol Rep 15, 541–548 (2013). https://doi.org/10.1007/s11912-013-0343-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-013-0343-3

Keywords

Search

Navigation